R&D/Clinical Trials

Results from the COCOON study showed that Rybrevant plus Lacluze reduced grade 2 or higher dermatologic events by 50% compared to standard care in patients with epidermal growth factor receptor-mutated non-small cell lung cancer.

Results from multiple clinical trials showed that Tagrisso demonstrated survival benefits in EGFR-mutated non-small cell lung cancer, both as monotherapy and in combination therapies.

Jennifer Kyle, CEO and founder of Condor, discusses the inspiration behind creating a financial cloud platform specifically for biopharma R&D.

Research also showed that the test has a very low false positive rate.

The investment, which is a 25% increase from previous years, will support three new advanced manufacturing facilities, expansions at existing sites, and R&D efforts.

Results from the STEER and STRENGTH studies showed that OAV101 IT led to a 2.39-point improvement in motor function in patients with spinal muscular atrophy.

In the Phase III STOP-HS1 and STOP-HS2 trials, results show that patients treated with povorcitinib for hidradenitis suppurativa experienced a ≥50% reduction in the total abscess and inflammatory nodule count.

Company executives provide updates on cancer treatment pelareorep and other elements of the company’s pipeline.

In the Phase III CALYPSO trial, eneboparatide demonstrated statistical significance in achieving albumin-adjusted serum calcium normalization while eliminating the need for active vitamin D and oral calcium therapy in chronic hypoparathyroidism.

Jonathon Whitton, AuD, PhD, VP, auditory global program head, Regeneron, discusses how the focus of technology development is shifting toward ensuring safety and continuous hearing for children.

Data from the Phase III MINT trial found that Uplizna demonstrated a greater reduction in Myasthenia Gravis Activities of Daily Living score compared to placebo at week 26.

Artiva Biotherapeutics' CEO Fred Aslan, MD, explains the strategic advantages of pursuing both a company-sponsored trial and an investigator-initiated trial simultaneously.

New real-world and implementation study data highlight the efficacy of ViiV’s long-acting injectables for HIV prevention and treatment, with Apretude showing zero HIV acquisitions and Cabenuva maintaining high viral suppression rates.

Immunotherapy pioneer Mark Frohlich, MD, CEO of Indapta Therapeutics, discusses the promise of harnessing natural killer cells to reshape treatment for cancer and autoimmune disease.

Artiva Biotherapeutics’ CEO Fred Aslan, MD, identifies data points the company is prioritizing to demonstrate that results from certain trials will translate to similar efficacy across a range of autoimmune conditions.

Topline results from the Phase III VERITAC-2 trial found that vepdegestrant provided a statistically significant and clinically meaningful improvement in progression-free survival in patients with ER+/HER2- advanced or metastatic breast cancer.

Dr. Dina Radenkovic, CEO of Gameto, discusses the use of iPSCs in fertility treatments, the most significant scientific hurdles they've encountered in developing and scaling these therapies (particularly in relation to ovarian aging), and how they're addressing them.

Results from multiple Phase III trials of Icotrokinra in moderate-to-severe plaque psoriasis and a Phase IIb trial in ulcerative colitis successfully met all primary endpoints.

What biopharma companies need to know about this evolving regulatory pathway.

Aliya Omer, VP, US franchise head, breast cancer, AstraZeneca, discusses Lynparza’s role in reducing the risk of invasive disease recurrence or death in HR-positive breast cancer patients.

Artiva Biotherapeutics' CEO Fred Aslan, MD, discusses the concept of an immune reset and what the company is tracking in trials to assess its potential.

Jonathon Whitton, AuD, PhD, VP, auditory global program head, Regeneron, discusses how key regulatory designations, such as the FDA's Regenerative Medicine Advanced Therapy designation, facilitate accelerated development and commercialization of DB-OTO through increased collaboration with regulators.

Artiva Biotherapeutics' CEO Fred Aslan, MD, discusses two ongoing trials for autoimmunity indications in the US and how AlloNK differs from traditional B-cell depletion strategies.

Five-year data from Phase III trials demonstrated that 67.7% of patients moderate-to-severe plaque psoriasis treated with UCB’s Bimzelx achieved complete skin clearance.

Clinical trial results found that a majority of patients with atopic dermatitis who were treated with Ebgylss achieved complete or near complete skin clearance at three years on a single monthly maintenance dose.